AHRQ Brain Tumor MRS Tech Assessment Makes NCD Reversal Doubtful
This article was originally published in The Gray Sheet
Executive Summary
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment
You may also be interested in...
CMS Aims To Clarify Diagnostic Imaging National Coverage Approach
CMS will develop industry-specific draft guidance documents covering sectors such as durable medical equipment and imaging devices, according to CMS Lead Medical Officer Carlos Cano, MD
CMS Aims To Clarify Diagnostic Imaging National Coverage Approach
CMS will develop industry-specific draft guidance documents covering sectors such as durable medical equipment and imaging devices, according to CMS Lead Medical Officer Carlos Cano, MD
CMS Non-Coverage Ruling Delay Apt If Device Lacks Evidence – AdvaMed
CMS should defer to local carriers when an absence of data prevents the agency from discerning whether an item or service meets the standard for "reasonable and necessary," AdvaMed contends